How do leukaemia stem cells talk to the immune system in juvenile myelomonocytic leukaemia?
Find out how JMML cells are able to switch off the immune system, causing relapse.
Creating a new immunotherapy approach to fight aggressive medulloblastoma
Finding a way to use immunotherapy against a high-risk type of childhood brain tumour.
Confirming bloodstream markers of children’s kidney cancer
Identifying markers that can be used for a non-invasive test to diagnose and monitor Wilms tumour.
A living review of new treatments for children and young people with relapsed and refractory rhabdomyosarcoma
Developing a living systematic review of studies into new treatments for relapsed and refractory rhabdomyosarcoma.
New treatments for relapsed rhabdomyosarcoma
Developing better models of rhabdomyosarcoma to test available treatments.
Investigating how regulatory regions of the genome communicate with cancer causing genes
Finding which regulatory regions of the genome are causing leukaemia by acting on the wrong gene
Improving treatment decisions and outcomes in low grade glioma
Development of a multi-factorial prognostic model to optimise treatment decision making and outcomes in paediatric low-grade glioma
A study to assess the usefulness of using a dye in combination with keyhole surgery in children with cancer
An open label, single centre, single arm, prospective feasibility study evaluating the effectiveness of near-infrared fluorescence(NIRF)using indo-cyanine green(ICG)in intra-abdominal or intra-thoracic minimally invasive surgery(MIS)in paediatric oncology.
Understanding treatment decision-making processes in families where a child or young person has relapsed/refractory rhabdomyosarcoma
Understanding treatment decision-making processes in families where a child or young person has relapsed/refractory rhabdomyosarcoma